nav emailalert searchbtn searchbox tablepage yinyongbenwen piczone journalimg journalInfo journalinfonormal searchdiv searchzone qikanlogo popupnotification paper paperNew
2024, 05, v.40 92-96
基于数据挖掘的中药治疗类风湿性关节炎用药规律分析
基金项目(Foundation): 国家中医药管理局标准化项目(编号:GZY-FJS-2020-219); 河南省重大公益专项(编号:201300310100); 河南省药品监督管理局科技计划项目(编号:2020DB050-55)
邮箱(Email): miaomingsan@163.com;
DOI: 10.13412/j.cnki.zyyl.20220728.001
发布时间: 2022-07-28
出版时间: 2022-07-28
网络发布时间: 2022-07-28
移动端阅读
摘要:

目的:基于数据挖掘探讨中药治疗类风湿性关节炎的组方用药规律。方法:以中国知网、万方数据库、维普数据库收录的期刊文献为资料来源,收集文献中所涉及的相关方剂,建立相应的数据库。使用Excel 2021和SPSS Statistic 25.0统计软件对符合纳入标准的方剂进行关联规则分析和因子分析。结果:共纳入130首方剂,共含142味中药,累计出现频数为1 480次。在纳入的统计数据中:频数≥22的中药共有20种,累计出现718次。前5味中药分别是当归(71次,9.87%)、甘草(63次,8.77%)、独活(51次,7.10%)、白芍(49次,6.82%)、防风(48次,6.69%);与其对应的清热药、解表药、补虚药在功效分类中出现最多,占比达到67.53%;药性药味中,药性以温、平的中药居多,药味以辛味、甘味的中药居多;归经分类中,归肝经、脾经、胃经的中药较多。类风湿性关节炎中医证型以风湿痹阻证和肝肾亏虚证占比最高。通过关联规则分析发现共有11种关联强度最高的药对组合,聚类分析可将药物分为4类,因子分析中7个公因子被提取出。结论:运用现代信息技术,将中医临床资料与大数据相结合进行规律探索,得出中药临床治疗类风湿性关节炎的规律:多使用补虚药,多选用入肝经的药物,最终反馈给临床,为指导临床更加安全合理用药及新处方研发提供依据。

Abstract:

Objective:To explore medication regularity of Chinese medicine in the treatment of rheumatoid arthritis based on data mining. Methods:The relevant prescriptions in the research articles retrieved from CNKI,Wanfang Data, and VIP were collected to establish a database. Excel 2021 and SPSS Statistic 25.0 statistical software were used for association analysis and factor analysis of Chinese medicinal prescriptions in line with the inclusion criteria. Results:A total of 130 prescriptions were obtained, involving 142 drugs with a total frequency of 1 480. According to the statistical data, there were 20 drugs with frequency ≥22,and the total frequency reached 718. The top 5 high-frequency drugs included ANGELICAE SINENSIS RADIX(71,9.87%),GLYCYRRHIZAE RADIX ET RHIZOMA(63,8.77%),ANGELICAE PUBESCENTIS RADIX(51,7.10%),PAEONIAE RADIX ALBA(49,6.82%),and SAPOSHNIKOVIAE RADIX(48,6.69%). In terms of efficacy, the heat-clearing, exterior-releasing, and deficiency-tonifying drugs accounted for a large proportion, reaching 67.53%. In terms of Yaoxing(药性),the majority of drugs were Wen(温) and Ping(平),and in terms of Yaowei(药味),drugs were mostly Xin(辛) and Gan(甘). In terms of Guijing(归经),most drugs acted on Ganjing(肝经),Pijing(脾经),and Weijing(胃经). In traditional Chinese medicine(TCM),rheumatoid arthritis was dominated by Fengshibizuzheng(风湿痹阻证) and Ganshenkuixuzheng(肝肾亏虚证). The association analysis revealed 11 drug combinations with strong association. Drugs were classified into four categories according to cluster analysis, and seven common factors were extracted by factor analysis. Conclusion:This study explored the medication regularity of Chinese medicine in the treatment of rheumatoid arthritis by virtue of TCM clinical data combined with big data with modern information technology. To be specific, the deficiency-tonifying drugs and those acting on Ganjing were frequently used. The above results were reported to the clinic, which is expected to provide a basis for clinical rational and safe medication and formulation of new prescriptions.

参考文献

[1]曹云祥,刘健,黄传兵,等.类风湿关节炎从瘀论治研究进展[J].中华中医药杂志,2021,36(2):983-985.

[2]刘蔚翔,姜泉.类风湿关节炎“湿、热、瘀”病机理论探析[J].中医杂志,2020,61(24):2148-2153.

[3]张宝成,李雪萍,陈云慧,等.基于三焦痹学说探讨桂枝芍药知母汤治疗类风湿性关节炎的中医理论机制[J].中华中医药杂志,2019,34(6):2535-2538.

[4]王序.外用清热利湿通络中药治疗湿热痹阻型类风湿性关节炎的效果研究[J].中国现代药物应用,2021,15(1):213-215.

[5]谢招虎,解静,吴晶金,等.类风湿关节炎中西医药物治疗研究概况[J].时珍国医国药,2020,31(7):1692-1695.

[6]吴丹,陈鸿,江红,等.基于UPLC-QTOF-MS/MS和TCMIP的续断治疗类风湿性关节炎活性成分筛选及作用机制分析[J].中国实验方剂学杂志,2021,27(16):131-140.

[7]中华人民共和国药典[M].中国医药科技出版社,国家药典委员会,2020.

[8]窦昌贵.中药学(成人高等教育药学专业教材)[M].上海:上海科学技术出版社,2013.

[9]Burmester G R,Pope J E.Novel treatment strategies in rheumatoid arthritis[J].Lancet,2017,389(10086):2338-2348.

[10]Smolen J S,Aletaha D,McInnes IB.Rheumatoid arthritis[J].Lancet,2016,388(10055):2023-2038.

[11]Hyndman I J.Rheumatoid arthritis:past,present and future approaches to treating the disease[J].Int J Rheum Dis,2017,20(4):417-419.

[12]Li X Z,Zhang S N.Herbal compounds for rheumatoid arthritis:Literatures review and cheminformatics prediction[J].Phytother Res,2020,34(1):51-66.

[13]Lü S,Wang Q,Li G,et al.The treatment of rheumatoid arthritis using Chinese medicinal plants:From pharmacology to potential molecular mechanisms[J].J Ethnopharmacol,2015,176:177-206.

[14]张林华,吴嘉瑞,张思旋,等.基于数据挖掘的中医治疗类风湿关节炎用药规律研究[J].中国医院用药评价与分析,2019,19(8):923-926.

[15]毛晓红.当归补血汤合桂枝汤治疗类风湿性关节炎33例疗效观察[J].中药药理与临床,2015,31(1):294-295.

[16]李李,李燕林.桂昆风湿合剂联合甲氨蝶呤治疗类风湿关节炎的临床研究[J].中药药理与临床,2019,35(5):155-158.

[17]文建庭,刘健,万磊,等.新安健脾系列方治疗类风湿关节炎的研究进展[J].风湿病与关节炎,2021,10(3):69-72,80.

[18]潘凌宇,陈燕,汪永忠.基于网络药理学探究桃红四物汤治疗类风湿性关节炎作用机制[J].中国药理学通报,2021,37(3):437-444.

[19]李伟,穆晓红,张晓哲,等.基于网络药理学探讨黄芪-桂枝药对治疗类风湿关节炎的作用机制[J].辽宁中医药大学学报,2021,23(6):58-64.

[20]熊平.数据挖掘算法与 Clementine 实践[M].北京:清华大学出版社,2011:143-167.

[21]俞春林,杜正彩,郝二伟,等.四类不同功效桂枝药对化学成分与药理作用的研究进展[J].中国实验方剂学杂志,2020,26(1):226-234.

[22]王文越,刘珊,吕琴,等.黄芪-当归药对益气活血药理作用研究进展[J].中国实验方剂学杂志,2021,27(6):207-216.

[23]张爱民.防己黄芪汤合独活寄生汤加减治疗类风湿性关节炎疗效观察[J].内蒙古中医药,2017,36(3):19.

[24]孙亮亮,章煌杰,鲁琛,等.补肾活血中药“杜仲-当归”治疗骨性关节炎的作用及机制研究[J].中华中医药学刊,2019,37(11):2639-2644,2826-2828.

[25]吴嘉瑞,郭位先,蔺梦娟,等.基于数据挖掘的国医大师颜正华含桑寄生处方用药规律分析[J].中国实验方剂学杂志,2015,21(22):197-202.

[26]段凯旋,李跃文,刘和波,等.基于网络药理学的羌活-独活药对抗炎作用机制研究[J].中国药房,2019,30(9):1241-1246.

[27]刘晨,王英豪,陈智煌,等.药对羌活与独活及其单味药治疗佐剂关节炎初步研究[J].辽宁中医药大学学报,2015,17(12):20-22.

[28]熊江华,李艳.中药复方对类风湿性关节炎干预机制的研究进展[J].中国实验方剂学杂志,2017,23(9):230-234.

[29]钟康骏,于鹏龙,崔琳,等.从正邪转化论卫气失调与类风湿关节炎发病[J].风湿病与关节炎,2021,10(2):45-46.

[30]郝悦,吕新亮.中成药治疗类风湿关节炎的研究近展[J].内蒙古中医药,2021,40(2):138-140.

[31]黄石,段贤春,曹云祥,等.类风湿关节炎从瘀论治研究进展[J].中华中医药杂志,2021,36(2):983-985.

[32]刘忠第,姜淼,谭勇,等.《临证指南医案》治疗痹证的用药规律和特色分析[J].中华中医药杂志,2016,31(2):405-409.

[33]黄淑敏,钟森杰,廖晓倩,等.基于中西医临床病证特点的类风湿性关节炎动物模型分析[J].中国中药杂志,2021,46(19):5152-5158.

[34]黄开月,罗慧,罗世锋,等.基于玄府理论探讨独活寄生汤辨治类风湿关节炎[J].中华中医药杂志,2020,35(11):5685-5687.

[35]陈旭.活络通痹汤治疗类风湿性关节炎的临床疗效观察[J].名医,2019,(11):229.

[36]邝高艳,严可,柴爽,等.加味独活寄生合剂治疗膝骨关节炎临床疗效及对关节液中IL-1,IL-6,TNF-α及NO的影响[J].中国实验方剂学杂志,2017,23(1):174-178.

基本信息:

DOI:10.13412/j.cnki.zyyl.20220728.001

中图分类号:R259

引用信息:

[1]张晓萍,白莉,冯思凡,等.基于数据挖掘的中药治疗类风湿性关节炎用药规律分析[J].中药药理与临床,2024,40(05):92-96.DOI:10.13412/j.cnki.zyyl.20220728.001.

基金信息:

国家中医药管理局标准化项目(编号:GZY-FJS-2020-219); 河南省重大公益专项(编号:201300310100); 河南省药品监督管理局科技计划项目(编号:2020DB050-55)

发布时间:

2022-07-28

出版时间:

2022-07-28

网络发布时间:

2022-07-28

检 索 高级检索